- Open Access
Correction to: Targeting hypoxia in tumor: a new promising therapeutic strategy
Journal of Experimental & Clinical Cancer Research volume 39, Article number: 43 (2020)
Correction to: J Exp Clin Cancer Res (2020) 39:8.
In the original publication of this manuscript , Fig. 1 contained a typographical error (‘Metabolic’ incorrectly written as ‘Metabolig’). The caption for Fig. 1 also contained typographical errors; “… regulated via O2-independent mechanisms.” should be instead have read “… regulated by O2-dependent mechanisms.”, and the caption should refer to 25 years and not 15 years. Figure 1 and its caption have now been corrected and are shown below.
In addition, the following sentences have been adjusted to remove ambiguity and correct the record:
‘Background’ section, “Hypoxia Inducible Factor-1 (HIF-1), is an α/β heterodimeric transcription factor that controls multiple oxygen-sensitive genes. In 1995 Semenza identified HIF-1α as a basic-helix-loop-helix-PAS heterodimer regulated by cellular oxygen tension” has been corrected to “In 1995, Semenza identified the Hypoxia Inducible Factor-1 (HIF-1) as a basic-helix-loop-helix-PAS α/β heterodimeric transcription factor regulated by cellular oxygen tension.”
‘Background’ section, “… as evidenced by the increased number of papers published on this topic in the last 15 years” has been corrected to “… as evidenced by the increased number of papers published on this topic in the last 25 years.”
The authors sincerely apologize for the inconvenience caused to the readers. The original article has been updated.
Bosco MC, et al. Targeting hypoxia in tumor: a new promising therapeutic strategy. Journal of Experimental & Clinical Cancer Research. 2020;39:8.
About this article
Cite this article
Bosco, M.C., Orazi, G.D. & Del Bufalo, D. Correction to: Targeting hypoxia in tumor: a new promising therapeutic strategy. J Exp Clin Cancer Res 39, 43 (2020). https://doi.org/10.1186/s13046-020-1532-1